Newstral
Michel Vounatsos
- BBiogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path3 min readbarrons.com
- Biogen tabs veteran pharma leader Viehbacher as next CEOseattletimes.com
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- New Alzheimers drug can slow disease: 'Mega blockbuster potential'New York Post
- BAlzheimer's-slowing drug labelled historicbbc.co.uk
- TBiogen Stock Soars On Promising Data From Late-Stage Alzheimer’s Drug Trialthestreet.com
- TStocks Resume Slump, Apple, Biogen, Elon Musk And Hurricane Ian - Five Things To Knowthestreet.com
- IBiogen tops Q2 2022 earnings and revenue estimatesinvezz.com
- Biogen chops expenses in Q2, raises 2022 profit forecastSeattle Times
- BWho Will Lead Biogen? Here Are Some Likely Picks.3 min readbarrons.com
- InnovationRx: Cerebral Stops ADHD Prescribing; Plus, Big Sales For Covid VaccinesForbes
- Biogen seeks new chief, cuts Aduhelm spendingArkansas Online
- An Alzheimer’s Drug Was Supposed to Be a Blockbuster for Biogen. Its Failure Cost the CEO His Job.observer.com
- Pfizer vaccine brought in more than $13B in sales - Tue, 03 May 2022 PSTThe Spokesman-Review
- Biogen to replace CEO after Alzheimer’s drug flopsjournalrecord.com
- MBeset by challenges with its Alzheimer's disease drug, Biogen pivots3 min readmarketwatch.com
- BBiogen Searches for New CEO in Wake of Struggles With Alzheimer's Drug 4 min readbarrons.com
- Change at the top for Biogen after Alzheimer's drug flops - Tue, 03 May 2022 PSTapnews.com
- Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug AduhelmForbes
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.